Around a thousand women in England with an incurable form of breast cancer will gain access to a life-extending treatment on the NHS after an earlier decision was reversed. Enhertu is the first licensed targeted treatment for HER2-low breast cancer that cannot be surgically removed or has spread elsewhere in the body. Clinical trials found patients receiving the drug survived for around two years on average, nearly seven months longer than those receiving chemotherapy. The National Institute for Health and Care Excellence rejected widespread NHS use in England in 2024 because of cost-effectiveness concerns, but has now approved it following a new commercial agreement. Breast Cancer Now described the decision as a 'milestone victory', while acknowledging that patients had missed out during the delay. Women living with metastatic breast cancer have welcomed the announcement, describing the additional months as precious opportunities to see children grow, celebrate family milestones, and make memories together. Campaigners are now calling for equivalent NHS access in Wales and Northern Ireland. See